Abstract
Two series of water soluble novel conjugates of the photosensitizer hypericin were prepared and evaluated for their use as agents for photodynamic therapy, with covalently and non-covalently loaded hypericin on functionalised, hydrolytically degradable inorganic-organic hybrid polyphosphazenes. The conjugates showed excellent aqueous solubility and similar fluorescence spectra to pristine hypericin Detailed in vitro investigations revealed that the substances were non-toxic in the dark over a wide concentration range, but displayed phototoxicity upon irradiation. Cell uptake studies showed rapid uptake with localization of hypericin observed in endoplasmic reticulum, Golgi complex and particularly in the lysosomes. Furthermore, a DNA fragmentation assay revealed that the photosensitizer conjugates are efficient inducers of apoptosis with some tumor cell selectivity caused by faster and enhanced accumulation in A431 than in HaCaT cells, and thus a moderately higher phototoxicity of A431 compared to HaCaT cells. These novel photosensitizer conjugates hence represent viable hydrolytically degradable alternatives for the advanced delivery of hypericin.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
P. Agostinis, A. Vantieghem, W. Merlevede and P. A. de Witte, Hypericin in cancer treatment: more light on the way, Int. J. Biochem. Cell Biol., 2002, 34, 221.
M. Alecu, C. Ursaciuc, F. Halalau, G. Coman, W. Merlevede, E. Waelkens and P. de Witte, Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin, Anticancer Res., 1998, 18, 4651.
M. Blank, G. Kostenich, G. Lavie, S. Kimel, Y. Keisari and A. Orenstein, Wavelength-dependent properties of photo-dynamic therapy using hypericin in vitro and in an animal model, Photochem. Photobiol., 2002, 76, 335.
I. Cavarga, P. Brezani, M. Cekanova-Figurova, P. Solar, P. Fedorocko and P. Miskovsky, Photodynamic therapy of murine fibrosarcoma with topical and systemic administration of hypericin, Phytomedicine, 2001, 8, 325.
C. S. Head, Q. Luu, J. Sercarz and R. Saxton, Photodynamic therapy and tumor imaging of hypericin-treated squamous cell carcinoma, World J. Surg. Oncol, 2006, 4, 87.
M. Olivo, H. Y. Du and B. H. Bay, Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy, Curr. Clin. Pharmacol, 2006, 1, 217.
R. Sanovic, T. Verwanger, A. Hard and B. Krammer, Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma, Photodiagn. Photodyn. Ther., 2011, 8, 291.
C. L. Saw, M. Olivo, K. C. Soo and P. W. Heng, Delivery of hypericin for photodynamic applications, Cancer Lett., 2006, 241, 23.
P. S. P. Thong, M. Olivo, W. W. L. Chin, R. Bhuvaneswari, K. Mancer and K. C. Soo, Clinical application of fluorescence endoscopic imaging using hypericin for the diagnosis of human oral cavity lesions, Br. J. Cancer, 2009, 101, 1580.
I. Zupko, A. R. Kamuhabwa, M. A. D’Hallewin, L. Baert and P. A. De Witte, In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors, Int. J. Oncol, 2001, 18, 1099.
V. Engelhardt, B. Krammer and K. Plaetzer, Antibacterial photodynamic therapy using water-soluble formulations of hypericin or mTHPC is effective in inactivation of Staphylococcus aureus, Photochem. Photobiol. Sci., 2010, 9, 365.
A. Karioti and A. R. Bilia, Hypericins as potential leads for new therapeutics, Int. J. Mol. Sci., 2010, 11, 562.
B. Krammer and T. Verwanger, Molecular response to hypericin-induced photodamage, Curr. Med. Chem., 2012, 19, 793.
E. Buytaert, J. Y. Matroule, S. Durinck, P. Close, S. Kocanova, J. R. Vandenheede, P. A. de Witte, J. Piette and P. Agostinis, Molecular effectors and modulators of hyperi-cin-mediated cell death in bladder cancer cells, Oncogene, 2008, 27, 1916.
M. Zeisser-Labouebe, N. Lange, R. Gurny and F. Delie, Hypericin-Ioaded nanoparticles for the photodynamic treatment of ovarian cancer, Int. J. Pharm., 2006, 326, 174.
A. Huygens, A. R. Kamuhabwa and P. A. de Witte, Stability of different formulations and ion pairs of hypericin, Eur. J. Pharm. Biopharm., 2005, 59, 461.
A. S. Derycke and P. A. De Witte, Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-llposomes, Int. J. Oncol, 2002, 20, 181.
A. Kubin, P. Meissner, F. Wierrani, U. Burner, A. Bodenteich, A. Pytel and N. Schmeller, Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-hypericin, Photochem. Photobiol, 2008, 84, 1560.
M. Van De Putte, T. Roskams, G. Bormans, A. Verbruggen and P. A. De Witte, The impact of aggregation on the bio-distribution of hypericin, Int. J. Oncol, 2006, 28, 655.
A. Kubin, H. G. Loew, U. Burner, G. Jessner, H. Kolbabek and F. Wierrani, How to make hypericin water-soluble, Pharmazie, 2008, 63, 263.
J. Vandepitte, B. Van Cleynenbreugel, K. Hettinger, H. Van Poppel and P. A. de Witte, Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder, Cancer Chemother. Pharmacol, 2011, 67, 775.
J. Vandepitte, M. Roelants, B. Van Cleynenbreugel, K. Hettinger, E. Lerut, H. Van Poppel and P. A. de Witte, Biodistribution and photodynamic effects of polyvinylpyrrolidone-hypericin using multicellular spheroids composed of normal human urothelial and T24 transitional cell carcinoma cells, J. Biomed. Opt, 2011, 16, 018001.
R. Duncan, Polymer therapeutics as nanomedicines: new perspectives, Curr. Opin. Biotechnol., 2011, 22, 492.
R. Duncan and S. C. Richardson, Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges, Mol. Pharm., 2012, 9, 2380.
E. Markovsky, H. Baabur-Cohen, A. Eldar-Boock, L. Omer, G. Tiram, S. Ferber, P. Ofek, D. Polyak, A. Scomparin and R. Satchi-Fainaro, Administration, distribution, metabolism and elimination of polymer therapeutics, J. Controlled Release, 2012, 161, 446.
R. Gaspar and R. Duncan, Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics, Adv. Drug Delivery Rev., 2009, 61, 1220.
V. Bühler, Polyvinylpyrrolidone Excipients for Pharmaceuticals, 2005.
H. A. Ravin, A. M. Seligman and J. Fine, Polyvinyl Pyrrolidone as a Plasma Expander, N. Engl. J. Med., 1952, 247, 921.
H. R. Allcock and N. L. Morozowich, Bioerodible polyphos-phazenes and their medical potential, Polym. Chem., 2012, 3, 578.
A. Andrianov, Water-Soluble Polyphosphazenes for Biomedical Applications, J. Inorganic Organomet Polym. Mater., 2006, 16, 397.
I. Teasdale, S. Wilfert, I. Nischang and O. Brllggemann, Multifunctional and biodegradable polyphosphazenes for use as macromolecular anti-cancer drug carriers, Polym. Chem., 2011, 2, 828.
H. Henke, S. Wilfert, A. Iturmendi, O. Brllggemann and I. Teasdale, Branched polyphosphazenes with controlled dimensions, J. Polym. Sci., Part A: Polym. Chem., 2013, 51, 4467.
I. Teasdale and O. Brllggemann, Polyphosphazenes: Multifunctional, Biodegradable Vehicles for Drug and Gene Delivery, Polymers, 2013, 5, 161.
S. Wilfert, A. Iturmendi, W. Schoefberger, K. Kryeziu, P. Heffeter, W. Berger, O. Brllggemann and I. Teasdale, Water-soluble, biocompatible polyphosphazenes with controllable and pH-promoted degradation behavior, J. Polym. Sci., Part A: Polym. Chem., 2014, 52, 287.
H. Falk, J. Meyer and M. Oberreiter, A Convenient Semisynthetic Route to Hypericin, Monatsh. Chem., 1993, 124, 339.
A. K. Andrianov, A. Marin and P. Peterson, Water-Soluble Biodegradable Polyphosphazenes Containing N-Ethylpyrro-lidone Groups, Macromolecules, 2005, 38, 7972.
I. Teasdale, M. Waser, S. Wilfert, H. Falk and O. Brllggemann, Photoreactive, water-soluble conjugates of hypericin with polyphosphazenes, Monatsh. Chem., 2012, 143, 355.
Y. F. Ho, M. H. Wu, B. H. Cheng, Y. W. Chen and M. C. Shih, Lipid-mediated preferential localization of hypericin in lipid membranes, Biochim. Biophys. Acta, 2009, 1788, 1287.
J. Knaup, Treatment of squamous cell carcinoma of epidermolysis bullosa patients by photodynamic therapy: an in vitro study, Master thesis, University of Salzburg, 2008.
A. L. Vandenbogaerde, E. M. Delaey, A. M. Vantieghem, B. E. Himpens, W. J. Merlevede and P. A. de Witte, Cytotoxicity and antiproliferative effect of hypericin and derivatives after photosensitization, Photochem. Photobiol., 1998, 67, 119.
M. Blank, M. Mandel, S. Hazan, Y. Keisari and G. Lavie, Anti-cancer activities of hypericin in the dark, Photochem. Photobiol., 2001, 74, 120.
P. Agostinis, A. Donella-Deana, J. Cuveele, A. Vandenbogaerde, S. Sarno, W. Merlevede and P. de Witte, A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives, Biochem. Biophys. Res. Commun, 1996, 220, 613.
M. Blank, G. Lavie, M. Mandel, S. Hazan, A. Orenstein, D. Meruelo and Y. Keisari, Antimetastatic activity of the photodynamic agent hypericin in the dark, Int. J. Cancer, 2004, 111, 596.
V. Huntosova, D. Buzova, D. Petrovajova, P. Kasak, Z. Nadova, D. Jancura, F. Sureau and P. Miskovsky, Development of a new LDL-based transport system for hydrophobic/amphi-philic drug delivery to cancer cells, Int. J. Pharm., 2012, 436, 463.
R. Penjweini, N. Smisdom, S. Deville and M. Ameloot, Transport and accumulation of PVP-Hypericin in cancer and normal cells characterized by image correlation spectroscopy techniques, Biochim. Biophys. Acta, 2014, 1843, 855.
I. G. England, L. Naess, R. Blomhoff and T. Berg, Uptake, intracellular transport and release of 125I-poIy(vinyIpyrroll-done) and [14C]-sucrose-asiaIofetuin in rat liver parenchymal cells. Effects of ammonia on the intracellular transport, Biochem. Pharmacol., 1986, 35, 201.
A. P. Castano, T. N. Demidova and M. R. Hamblin, Mechanisms in photodynamic therapy: part one - photosensiti-zers, photochemistry and cellular localization, Photodiagn. Photodyn. Ther., 2004, 1, 279.
D. Kessel, Y. Luo, P. Mathieu and J. J. Reiners Jr., Determinants of the apoptotic response to lysosomal photo-damage, Photochem. Photobiol., 2000, 71, 196.
U. Repnik, V. Stoka, V. Turk and B. Turk, Lysosomes and lysosomal cathepsins in cell death, Biochim. Biophys. Acta, 2012, 1824, 22.
E. Buytaert, G. Callewaert, N. Hendrickx, L. Scorrano, D. Hartmann, L. Missiaen, J. R. Vandenheede, I. Heirman, J. Grooten and P. Agostinis, Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy, FASEBJ., 2006, 20, 756.
M. Shi, T. Zhang, L. Sun, Y. Luo, D. H. Liu, S. T. Xie, X. Y. Song, G. F. Wang, X. L. Chen, B. C. Zhou and Y. Z. Zhang, Calpain, Atg5 and Bak play important roles in the crosstalk between apoptosis and autophagy induced by influx of extracellular calcium, Apoptosis, 2013, 18, 435.
Z. Jiang, Z. Hu, L. Zeng, W. Lu, H. Zhang, T. Li and H. Xiao, The role of the Golgi apparatus in oxidative stress: is this organelle less significant than mitochondria?, Free Radical Biol. Med., 2011, 50, 907.
R. Ritz, F. Roser, N. Radomski, W. S. Strauss, M. Tatagiba and A. Gharabaghi, Subcellular colocalization of hypericin with respect to endoplasmic reticulum and Golgi apparatus in glioblastoma cells, Anticancer Res., 2008, 28, 2033.
J. Berlanda, T. Kiesslich, C. B. Oberdanner, F. J. Obermair, B. Krammer and K. Plaetzer, Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells, J. Environ. Pathol. Toxicol. Oncol, 2006, 25, 173.
V. Sackova, P. Fedorocko, B. Szilardiova, J. Mikes and J. Kleban, Hypericin-induced photocytotoxicity is connected with G2/M arrest in HT-29 and S-phase arrest in U937 cells, Photochem. Photobiol, 2006, 82, 1285.
H. B. Lee, A. S. Ho and S. H. Teo, p53 Status does not affect photodynamic cell killing induced by hypericin, Cancer Chemother. Pharmacol, 2006, 58, 91.
J. Mikes, J. Koval, R. Jendzelovsky, V. Sackova, I. Uhrinova, M. Kello, L. Kulikova and P. Fedorocko, The role of p53 in the efficiency of photodynamic therapy with hypericin and subsequent long-term survival of colon cancer cells, Photochem. Photobiol. Sci., 2009, 8, 1558.
X. Wang, Y. Guo, S. Yang, C. Wang, X. Fu, J. Wang, Y. Mao, J. Zhang and Y. Li, Cellular and molecular mechanisms of photodynamic hypericin therapy for nasopharyngeal carcinoma cells, J. Pharmacol. Exp. Ther., 2010, 334, 847.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Electronic supplementary information (ESI) available. See DOI: 10.1039/c4pp00251b
Rights and permissions
About this article
Cite this article
Feinweber, D., Verwanger, T., Brüggemann, O. et al. Applicability of new degradable hypericin-polymer-conjugates as photosensitizers: principal mode of action demonstrated by in vitro models. Photochem Photobiol Sci 13, 1607–1620 (2014). https://doi.org/10.1039/c4pp00251b
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/c4pp00251b